Home › Merck to Present New Clinical Data on JANUVIA (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association
 

Keywords :   


Merck to Present New Clinical Data on JANUVIA (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the American Diabetes Association

2014-06-06 14:00:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will present 13 new studies and analyses, including data for its DPP-4 inhibitor JANUVIA (sitagliptin) and for its investigational once-weekly DPP-4 inhibitor omarigliptin, at the 74th Scientific Sessions of the American Diabetes Association (ADA) being held in San Francisco, June 13-17, 2014. Several analyses of patient data in real-world settings will also be presented. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orKim Hamilton908-423-6831 or 908-391-0131orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of type data present

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.06Atlantic Tropical Weather Outlook
02.06Eastern North Pacific Tropical Weather Outlook
02.06Shops rush for Christmas stock as shipping costs surge
02.06Successful entrepreneurs dont worry about being different
02.06Eastern North Pacific Tropical Weather Outlook
02.06Atlantic Tropical Weather Outlook
01.06Mining for Pearlizing Agent 
01.06The Power of Zinc Pyrithione
More »